Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Down 1.5%

United Therapeutics stock opened at $513.12 on Friday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The firm has a market capitalization of $22.01 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 1.74 and a beta of 0.59. The firm has a 50 day simple moving average of $533.08 and a 200 day simple moving average of $537.36.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.41 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth $26,000. Toth Financial Advisory Corp boosted its stake in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in United Therapeutics during the second quarter worth about $30,000. Finally, WealthCollab LLC grew its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.